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536he polymer-based, sirolimus-eluting Cypher (Cordis
orp., Warren, New Jersey) drug-eluting stent (CDES) has
ecome a common treatment for patients with symptomatic
oronary artery disease undergoing percutaneous coronary
ntervention. However, the long-term safety of CDES has
een called into question owing to concerns about late stent
hrombosis secondary to impaired arterial healing charac-
erized by delayed re-endothelialization and persistence of
brin (1,2). Emerging evidence suggests that drug delivery
olymers may play an important role in the pathophysiology
f impaired healing by provoking inflammatory cell infiltra-
ion and/or causing long-term drug sequestration within the
rterial wall (3–5). Moreover, the versatility of CDES for
nterventions involving multiple stents such as overlap or
ifurcations is likely limited by local arterial toxicity, which
ccurs when drug and polymer concentrations are substan-
tially increased (6–8).
The ISAR (individualizable
drug-eluting stent [DES] system
to abrogate restenosis) polymer-
free DES was recently developed
to allow for dose-adjustable, on-
site coating of stents with a mi-
croporous surface without the ob-
ligate use of a polymer (9). Stents
coated with sirolimus using this
technology demonstrate efficacy
equal to that of polymeric DES in
reducing restenosis in humans at
9-month follow-up (10), but
whether they heal more efficiently
and have more versatility than
CDES is unknown. Additionally,
estradiol, which in animal models
prevents smooth muscle prolifera-
tion and enhances endothelializa-
tion after vascular injury (11), may
be able to improve healing if de-
ivered on the stent in combination with sirolimus.
The aim of this study was to compare the healing
roperties of polymer-free bare-metal stents (BMS) and
olymer-free sirolimus-eluting stents (SES) or sirolimus-
luting stents plus estradiol (SESED) to those of com-
ercially available CDES in an established rabbit model of
verlapping stent placement.
ethods
tent coating protocol. The ISAR polymer-free stent plat-
orm used to prepare the SES and SESED DES consists
f a 316-liter, stainless steel, microporous stent in a dispos-
ble coating cartridge (Yukon DES, Translumina, Hechin-
bbreviations
nd Acronyms
MS  bare-metal stent(s)
DES  Cypher drug-eluting
tent(s)
ES  drug-eluting stent(s)
L  interleukin
SAR  individualizable drug-
luting stent system to
brogate restenosis
M  light microscopy
C  organoid culture
EM  scanning electron
icroscopy
ES  sirolimus-eluting
tent(s)
ESED  sirolimus-eluting
tent(s) plus estradiol
EGF  vascular endothelial
rowth factoren, Germany). Coating was performed as previously de- ncribed (9) with either SES alone (1% concentration) or
ith SESED, both at 1%. The release kinetics for the
ES- and SESED-coated ISAR stents have been pub-
ished (9,12). The 1% SES solution used in this study was
elected on the basis of results from a dose-finding study in
umans (13). The ISAR BMS (Yukon, Translumina)
erved as control stents.
tent procedure. The protocol was approved by the Insti-
utional Animal Care and Use Committee of the Massa-
husetts General Hospital, and all experiments were con-
ucted according to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.”
wenty-five New Zealand White rabbits (3.7 to 4.1 kg)
uccessfully underwent stent implantation under anesthesia
ith inhaled isoflurane for 28-day analysis by light micros-
opy (LM) or scanning electron microscopy (SEM). Using
tandard fluoroscopy, balloon injury was performed in both
liac arteries. Subsequently, animals were randomly allocated
o receive a pair of overlapping SES, SESED, BMS, or
DES in 1 iliac artery and a different pair of overlapping
tents in the other iliac artery. All stents were deployed at
he area of injury at nominal pressure. Mean percentage of
verlap was 53.1  6.9% for CDES, and 49.0  2.6%, 51.1
3.2%, and 52.7  4.7% for SES, SESED and BMS,
espectively (p  NS). The CDES were 3.0  18 mm. All
SAR stents were 3.0  16 mm. The strut thickness of the
SAR stents is 87 m, and that of CDES is 140 m.
An additional 5 animals received balloon injury and single
tent placement in each iliac artery, as described in preced-
ng text, for organoid culture (OC).
ntithrombotic regimen. All animals were pre-treated with
spirin, 40 mg orally (approximately 10 mg/kg), 24 h before
tenting, and aspirin was continued until sacrifice. In addi-
ion, heparin (150 IU/kg) was administered intra-arterially
efore catheterization procedures.
issue harvest and processing. Twenty-eight days after
tenting, animals assigned for LM or SEM were re-
nesthetized, and follow-up angiography was performed to
erify stent patency and position. Euthanasia was accom-
lished with an overdose of Beuthanasia-D given intrave-
ously under deep anesthesia. Stented arteries were perfu-
ion fixed in-situ with 10% buffered formalin. Arteries were
repared for LM as previously described (3).
Animals with stents for OC were reanesthetized in the
ame way at 14 days after stent placement.
Arteries were perfused in-situ with Ringer’s lactate solu-
ion and placed in culture conditions.
canning electron microscopy. Stented arteries were har-
ested at 28 days, longitudinally cut, and analyzed by SEM,
s previously described (14).
rganoid culture. The 14-day stent implants using SES,
ESED, and BMS were used for OC. (The CDES were
ot tested owing to limited availability and cost of devices.)
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537ntact specimens were maintained in serum-free Dulbecco’s
odified Eagle’s medium kept in humidified 95% air/5%
O2 at 37°C. The media from each artery were collected
fter 48 hours, concentrated, and analyzed using a Cytokine
rray kit (RayBio Human Cytokine Array III, RayBiotech,
nc., Norcross, Georgia). Membrane blots were imaged
ith a Chemi-doc (Bio-Rad, Hercules, California) and
nalyzed using image analysis software (Quantity One,
io-Rad).
ata analysis. All arterial segments were examined blindly.
omputerized planimetry was performed on all stented
rterial sections, as previously described (14). Percent lumi-
al stenosis was calculated with the following formula:
eointimal area divided by the external elastic lamina times
00. Fibrin deposition, the number of giant cells around
tent struts, and heterophil/eosinophil infiltration were
uantitated and expressed as the number of struts sur-
ounded by fibrin, the percent of struts surrounded by giant
ells, and the total number of heterophils/eosinophils lining
he lumen of the vessel, respectively.
tatistical analysis. Light microscopy and SEM data are
xpressed as mean  SD. For multiple group comparisons
mong arteries stented with different devices, we utilized a
-way analysis of variance. If the variance ratio test (F-test)
as significant, a more detailed post hoc analysis of differ-
nces between groups of arteries was made using a Tukey-
ramer honest significance difference test. For comparisons
f overlapping to nonoverlapping segments within groups
nd for analysis of cytokine array between groups, a paired
tudent t test was utilized. The normality of distribution
as tested using the Wilk-Shapiro test. A p value  0.05
as considered significant.
esults
urgical outcome. All 30 animals (SES, n  14 arteries [8
M, 3 SEM, 3 OC]; SESED, n  14 arteries [8 LM, 3
EM, 3 OC]; bare-metal ISAR DES [BMS], n  18 [10
M, 4 SEM, 4 OC]; CDES, n  13 arteries [10 LM and
SEM]) were in good health for the duration of the study,
nd all stents were widely patent at follow-up angiography
ithout incidence of dissection, thrombosis, stent migra-
ion, or aneurysm formation.
istology and SEM. Scanning electron microscopy of 28-
ay stents demonstrated almost complete (i.e., 90% to
00%) endothelial coverage of arteries implanted with
onpolymer-based ISAR BMS within the overlapping and
onoverlapping segments of the stent, irrespective of the
resence of drug coating (Table 1, Fig. 1A). The CDES
emonstrated significantly decreased endothelial coverage
ompared with SES, SESED, and BMS within the
onoverlapping segments (80.0  5.0% vs. 95.3  5.0%,
7.5  2.5%, and 96.7  3.8%, respectively; p  0.0028)
nd the overlapping segments (48.3  2.9% vs. 85.8  S.9%, 90.8  6.3%, and 89.2  6.3%, respectively; p 
.0001) (Fig. 1B). In contrast to all nonpolymer-based
SAR stents, the degree of endothelialization was signifi-
antly less in overlapped than in nonoverlapped CDES
ections (p  0.018).
In arteries implanted with CDES, bare stent wires were
ccasionally observed within the nonoverlapping segment
nd more frequently at the overlap site along with adherent
hite cells and platelets (Fig. 1A). Moreover, the partially
ndothelialized luminal surface between stent struts was
haracterized by loose endothelial cell junctions and scat-
ered inflammatory cells. In contrast, SES, SESED, and
MS showed a confluent layer of endothelial cells through-
ut the stent and little or no evidence of inflammatory cell
nfiltration (Fig. 1A insets).
The percentage of struts surrounded by fibrin in the
onoverlapping segments of CDES was considerably in-
reased in comparison with SES, SESED, and BMS
25.2 15.3% vs. 3.2 3.9%, 6.4 6.7%, and 2.8 5.0%,
espectively; p  0.0002). Overlapping segments of CDES
nly exacerbated this trend, with nearly one-half of the stent
truts in the overlap area exhibiting some degree of fibrin
eposition versus SES, SESED, and BMS (47.8 20.9%
s. 11.5  10.8%, 15.7  12.9%, and 7.90  9.77%; p 
.0001, respectively). Fibrin deposition was significantly
reater in overlapped CDES than in nonoverlapped CDES
p 0.0019) and in SESED (p 0.02) (Fig. 2 and Table
). Remarkably, there was no difference between BMS and
olymer-free DES.
The number of heterophils/eosinophils on the luminal
urface of SES, SESED, and BMS was negligible (1
ell) in the nonoverlapping segment and only marginally
igher in CDES (p  NS) (Table 1). Overlapping stents
esulted in a small nonsignificant increase in these luminal
nflammatory cells in the SES, SESED, and BMS (6.5 
.57, 4.2  3.6, and 2.3  1.4 cells, respectively), whereas
verlapping CDES showed a substantial rise in the number
f luminal eosinophils to 34.7  17.6 cells (p  0.0001 vs.
onoverlapped CDES). In overlapped CDES sections,
osinophils were also significantly higher than were seen in
verlapped SES, SESED, and BMS (p  0.0001).
Giant cells were observed throughout the stent in all stent
roups, with significant increases between nonoverlapping
nd overlapping sections observed only in the case of CDES
p  0.007) (Table 1, Fig. 2).
orphometric analysis. There were no significant differ-
nces in neointimal thickness within nonoverlapping areas
etween CDES and SES, SESED, and BMS (0.09 
.03 mm vs. 0.10  0.03 mm, 0.07  0.01 mm, and 0.09
0.03 mm; p  NS), although the CDES group showed
ecreased neointimal thickening versus the SES, SESED,
nd BMS groups at the overlap site (Table 1, Fig. 3). The
ESED tended to have less neointimal thickness and
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538ercent stenosis as compared with SES alone within both
he nonoverlapping and overlapping segments (Table 1).
The internal elastic lamina and external elastic lamina
reas were greater in the CDES group than in any other
tent group, both in overlapping and nonoverlapping areas.
hese indexes of positive remodeling did not translate into
hanges in medial area, however, as no differences in this
easure were noted among the groups (Table 1).
There was no difference in mean injury score between
tent groups at the nonoverlapping segment (SES, 0.78 
.26; SESED, 0.81  0.30; BMS, 0.98  0.26; CDES,
.02  0.15; p  NS). However, mean injury scores were
ignificantly different at the overlap site between CDES and
ES (1.15  0.13 vs. 0.74  0.24; p  0.001), CDES and
MS (1.15 0.13 vs. 0.93 0.32; p 0.05), and SES and
ESED (0.74  0.24 vs. 1.00  0.22; p  0.03) (Table
Table 1. Morphometric and Histologic Characteristics of DES at 28 Days
SES SESED
Nonoverlap
Strut thickness, m 87 87
Morphometry
IEL, mm2 4.68 0.52 5.21 0.37
EEL, mm2 5.24 0.65 5.73 0.41
Medial area, mm2 0.56 0.17 0.51 0.12
Intimal thickness, mm 0.10 0.03 0.07 0.01
% stenosis 25.4 7.9 17.2 1.6
Injury score 0.78 0.26 0.81 0.30
Histology
% struts surrounded by ﬁbrin 3.22 3.9 6.44 6.7
Eosinophils (lumen) 0.00 0.00 0.40 0.54
% struts surrounded by giant cells 32.7 15.2 31.9 14.5
% endothelialization 95.3 5.03 97.5 2.50
Overlap
Morphometry
IEL, mm2 5.29 0.34 5.80 0.26
EEL, mm2 5.64 0.36 6.22 0.22
Medial area, mm2 0.35 0.05 0.41 0.05
Intimal thickness, mm 0.16 0.03 0.15 0.03
% stenosis 31.9 2.7 26.7 4.1
Injury score 0.74 0.24 1.00 0.22
Intimal thickness/injury score 0.24 0.03 0.15 0.03
Histology
% struts surrounded by ﬁbrin 11.5 10.8 15.7 12.9
Eosinophils (lumen) 6.5 0.57 4.2 3.63
% struts surrounded by giant cells 42.0 17.3 34.6 19.3
% endothelialization 85.8 2.89 90.8 6.29
Values aremean SD. *Only comparisons that yielded significant differences are shown.†p 0.001
SES or BMS, p NS for CDES versus SESED. §p 0.02 CDES versus SESED but NS for CDES vers
BMS bare-metal stent(s); CDES Cypher drug-eluting stent(s); EEL external elastic lamina; IE). When corrected for the degree of injury, differences in Sntimal thickness remained significant for CDES versus
ES and CDES versus BMS but not for CDES versus
ESED (Table 1).
rganoid culture. Using OC and protein array technology,
e investigated the effect of SES, SESED, and BMS on
ytokine and growth factor expression in arteries 14 days
fter stent placement. Relative protein expression of SES (n
3 arteries) and SESED (n  3 arteries) were normal-
zed to the corresponding BMS (n  4 arteries) and
xpressed as a ratio (SES/BMS or SESED/BMS). Figure
illustrates the relative expression levels of various proteins
nvolved in vascular healing and inflammation: interleukin
IL)-2, IL-4, IL-8, IL-10, macrophage-derived chemokine,
acrophage colony-stimulating factor, vascular endothelial
rowth factor (VEGF), and insulin-like growth factor.
aired statistical analyses showed no difference between
p Value*
S CDES
SES vs.
SESED
BMS vs.
SESED
CDES vs. SES,
SESED, BMS
7 140
0.35 6.27 0.37 NS 0.004 0.0001
0.39 6.82 0.47 NS 0.005 0.0001
0.07 0.56 0.15 NS NS NS
0.03 0.09 0.03 0.009 NS NS
4.8 20.5 4.1 0.003 NS NS
0.26 1.02 0.15 NS NS NS
5.0 25.2 15.3 NS NS 0.0002
0 5.3 10.2 NS NS NS
12.3 47.1 16.7 NS NS NS
3.82 80.0 5.0 NS NS 0.0028
0.35 6.73 0.59 NS NS 0.0001
0.39 7.07 0.64 NS NS 0.0001
0.05 0.34 0.06 NS NS NS
0.03 0.07 0.04 NS NS 0.0001
3.6 21.9 3.7 0.007 NS 0.007
0.32 1.15 0.13 0.03 NS †
0.03 0.07 0.03 0.05 NS ‡
9.77 47.8 20.9 NS NS  0.0001
1.41 34.7 17.6 NS NS 0.0001
20.1 60.7 10.1 NS NS §
6.3 48.3 2.9 NS NS 0.0001
S versus SES, p 0.05 for CDES versus BMSbutNS for CDES versus SESED.‡p 0.002CDES versus
or SES.
rnal elastic lamina; NS not significant; SESED sirolimus-eluting stent(s) plus estradiol.BM
8
4.62
5.04
0.42
0.09
20.4
0.98
2.78
0
46.0
96.7
5.60
5.96
0.37
0.15
28.4
0.93
0.20
7.90
2.0
49.7
89.2
for CDE
us BMSES/BMS and SESED/BMS in expression levels of
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539L-2, -4, -8, and -10. However, VEGF and macrophage
olony-stimulating factor exhibited significantly increased
rotein expression in SESED/BMS versus SES/BMS
p  0.05), and there was a strong trend toward up-
egulation of macrophage-derived chemokine and VEGF-1
n SESED/BMS compared with SES/BMS (p 0.07 for
DE+SESSES BMS
SES SES + E
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Figure 1. SEM and Quantitative Analysis of 28-Day Rabbit Iliac Artery Sten
Scanning electron microscopy (SEM) photographs and quantitative analysis of
mus-eluting stents plus estradiol (SESED), bare-metal stents (BMS), and Cyph
lap. (A) En-face examination demonstrates near-complete endothelial coverage
overlap region. However, there is marked absence of intact endothelium over
the nonoverlapping and overlapping sites (box) shows that the endoluminal s
inﬂammatory cells. However, CDES show widespread areas of exposed stent st
sinophils, macrophages, and platelets in the vicinity of stent struts. (B) Quantit
greater endothelialization than CDES at both the nonoverlapping and overlapp
tion in overlapping as compared with nonoverlapping areas, which does not o
sis) stents. *p  0.003 versus SES, SESED, BMS. †p  0.02 versus nonoverlapoth). fiiscussion
lthough polymer-based CDES have been shown to be
ffective in preventing in-stent restenosis in humans, this
pproach is associated with delayed healing and increased
isk of late stent thrombosis (1,2). We have shown for the
SED
Overlap
Non-Overlap
BMS
BMS CDES
CDES
BMS CDES
* †
palrevO
lants
iliac arteries implanted with overlapping sirolimus-eluting stents (SES), siroli-
g-eluting stents (CDES). The dashed lines indicate boundaries of stent over-
S, SESED, and BMS, with rare areas of exposed struts conﬁned to the
struts in CDES, especially in the overlapping segment. High magniﬁcation of
of SES, SESED, and BMS remains covered by endothelium with very few
nd incompletely endothelialized lumen with ﬁbrin, adherent heterophils/eo-
analysis of endothelial coverage: the SES, SESED, and BMS demonstrated
egments of the stent. For CDES, there is also signiﬁcantly less endothelializa-
n the ISAR (Individualizable drug-eluting stent System to Abrogate Resteno-
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540luted either SES or SESED have improved endothelial
overage and reduced inflammatory responses when com-
ared with polymer-based CDES in a rabbit iliac model of
verlapping stent placement. However, intimal suppression
as not as robust as with CDES, especially at overlapping
egments. These findings underscore the important role that
olymers play in both neointimal suppression and impaired
ealing.
ascular responses. In our previous work in the rabbit as well
s in the current study, we examined the histologic response to
verlapping CDES placement and found evidence of dose-
ependent arterial impairment of healing when comparing
verlapping with nonoverlapping segments (3). In both stud-
es, overlapping segments demonstrated significant increases in
eterophils/eosinophils, fibrin, and impaired endothelializa-
ion. In contrast, nonpolymeric ISAR DES showed no in-
reases in these variables with the exception of percent fibrin
or SESED. Neointimal formation was similar when com-
aring nonoverlapping sections of CDES with those of non-
olymeric stents, although CDES clearly suppressed intimal
hickness more effectively at overlapping segments, even when
orrected for the injury score, except in the case of SESED.
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Figure 2. 28-Day Histology of Overlapping and Nonoverlapping Stents
(A) High magniﬁcation (inset) photomicrographs of overlapping stent struts d
SES, SESED, and BMS versus CDES. The CDES show pronounced inﬂammator
niﬁcant increase in the percentage of struts surrounded by eosinophils in over
ments (C) in CDES versus the other nonpolymeric stents. The degree of giant
segments for SESED and CDES. *p  0.0001 versus SES, SESED, BMS. †p 
 0.02 for overlapping versus nonoverlapping segments. Abbreviations as in Fhe lack of effect of CDES on reducing intimal thickness at aonoverlapping segments versus BMS was unexpected, given
hat others have shown efficacy in this model when comparing
DES with its corresponding BMS (BxVelocity, Cordis
orp., Warren, New Jersey) (15) and might be due to the
ignificantly thinner strut thickness of the ISAR stents (87
m) compared with the CDES (140 m), a factor known to
e important in determining restenosis rates (16).
In contrast to the findings of Wessely et al. (9), who
mplanted SES-coated ISAR single stents in the porcine
oronary model, we found significantly decreased endothelial
overage in CDES compared with polymer-free DES and
MS in the nonoverlapping segment. Part of the explanation
or this may lie in the methods used to detect endothelializa-
ion (i.e., SEM in this study vs. LM). Scanning electron
icroscopy allows en-face examination of the whole stent
urface, whereas LM is limited to cross-sectional analysis.
nother explanation may lie in the differential response to
njury of the porcine versus rabbit models, with the pig
e-endothelializing at a quicker pace than the rabbit (17).
athophysiology of delayed healing. Current-generation
DES elute sirolimus from a nonbiodegradable polymer
atrix composed of polyethylene-co-vinyl acetate (PEVA)
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541ermanently in contact with the arterial wall. Although this
olymer has been reported to provoke chronic eosinophilic
nfiltration of the arterial wall suggestive of hypersensitivity,
causal relationship between inflammation and thrombosis
as been observed in a very small number of patients (2,4).
e observed substantial increases in luminal heterophils/
osinophils with CDES as compared with nonpolymeric
ES and BMS only at overlapping segments, although we
ound delayed endothelialization and increases in fibrin in
oth overlapped and nonoverlapped segments. This finding
uggests that increases in inflammatory cells cannot by
hemselves be responsible for delayed healing. We observed
his same effect in human pathology specimens from pa-
ients who formerly received either polymer-based DES or
MS implanted at similar times. Although there was
ncreased fibrin accumulation and significantly less endo-
helialization in DES versus BMS, inflammation scores
SES
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B2
SES+ED
A3
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B4
Figure 3. Nonoverlapping and Overlapping Sections in SES, SESED, BMS
(A1 to D1) Representative low-power photomicrographs of all 4 stent groups—
D2) The neointima of overlapping SES, SESED, and BMS consists of an organ
implanted arteries demonstrate impaired vascular healing with little neointima
uncovered). (A3 to D3) High-power views from boxed areas in A2 to D2 of ov
populate the immediate vicinity of overlapping stent struts in all groups. (A4 t
struts, particularly those uncovered by an appreciable neointima (hematoxylin
CDES struts (arrows), which are absent from SES, SESED, and BMS. Abbreviaere similar (2). This observation suggests that other wechanisms such as drug and drug-release kinetics, which
re affected by polymeric systems, may also be important in
he pathophysiology of delayed healing.
Although the rationale behind polymeric DES platforms
s to achieve controlled drug release, and therefore impres-
ive reductions in intimal formation, there are important
isks associated with this strategy resulting from local
ellular toxicity and/or drug overdose. Even though the total
ose of sirolimus is more than 2 times higher on the SES
nd SESED than on the CDES (CDES  1.4 g
irolimus/mm2 vs. ISAR 1% SES stent  3.1 g/mm2),
mounts well above that needed to effectively inhibit smooth
uscle and endothelial cells proliferation (18,19), we demon-
trated significantly improved healing in ISAR stents as com-
ared with CDES. Wessely et al. (9,15) demonstrated that
SAR rapamycin-coated stents elute two-thirds of their drug in
he first week and nearly all of the loaded dose by 21 days,
1
BMS
2
CDES
D1
D2
C3
C4
D3
D4
CDES
SESED, BMS, and CDES—within the nonoverlapping stent segment. (A2 to
yer of smooth muscle cells in a proteoglycan-rich matrix. In contrast, CDES
th at the overlap site (note that the struts of the innermost stent are mostly
ing stent strut sections (Movat Pentachrome stain). Occasional giant cells
Fibrin-rich areas were common in the area neighboring overlapping CDES
osin stain). Note the remnants of the polymer in the area once occupied by
s in Figure 1.C
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542n the pig coronary artery, tissue levels of rapamycin peak at 3
ays with the ISAR system and at 14 days with the CDES.
side from the biological reaction to the polymer itself, our
ata underscore the important role release kinetics play with
egard to both the healing characteristics and the antirestenotic
fficacy of these 2 stent systems.
An alternative approach to accelerate healing is local
odelivery of compounds that are known to inhibit smooth
uscle proliferation along with others known to accelerate
ndothelial regrowth after vascular injury, such as the
ormone estradiol (11,20). Prior work in animal models has
hown that estradiol promotes stent re-endothelialization
nd neointimal inhibition, although Adriaenssens et al. (12)
ecently reported no improvement in neointimal inhibition
hen rapamycin-coated stents were layered with 17--
stradiol in humans. Our data demonstrate no additional
ffect on endothelial coverage within overlapping and non-
verlapping segments of SESED as compared with SES,
lthough measures of neointimal formation (i.e., intimal
hickness and percent stenosis) tended to be lower with
ESED, especially in the overlapping segment when
orrected for injury. The explanation as to why we saw no
A
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Figure 4. Relative Protein Expression Levels of Chemokines, Growth Facto
Relative protein expression levels of (A) chemokines (macrophage-derived che
(vascular endothelial growth factor [VEGF] and insulin-like growth factor [IGF]-
polymeric SES, SESED, and BMS implanted arteries at 14 days as illustrated b
sion levels of SES or SESED over BMS. Abbreviations as in Figure 1.ifferences in endothelial coverage may lie in the time point mhosen. Given the relatively short time course of healing in
he rabbit, with near-complete endothelialization in all
SAR stents at 28 days, any improvements in coverage
ould be difficult to detect in this model at this time point.
rganoid culture of ISAR DES. Cytokines and growth factors
lay a major role in the cascade of biological events leading
o vascular inflammation and healing. We found that the
ddition of ED to the SES-coated nonpolymeric stent
aused a trend toward up-regulation in each of the 8
roteins examined, a trend that reached statistical signifi-
ance for macrophage colony-stimulating factor and VEGF.
acrophage colony-stimulating factor is known to facilitate
onocyte survival, monocyte-to-macrophage conversion,
nd macrophage proliferation (21). Monocyte-derived cells
re thought to play an important role in wound healing,
specially in formation of highly vascular scaffold tissue (22),
lthough their role in the process of re-endothelialization
fter vascular injury has not been well characterized. Vas-
ular endothelial growth factor is the most important
ngiogenic factor involved in migration and proliferation of
ndothelial cells, with higher levels correlating with healing
ersus quiescent endothelial surfaces (23,24). Our data
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543p-regulation of VEGF (along with enhanced endothelial-
zation) in ED-treated rat after carotid balloon injury. In
ggregate, these data suggest that the addition of ED to
ES may have had a favorable effect on vascular healing,
hich may have been detectable had an earlier time point
een chosen for pathology analysis.
linical implications. Impairment of vascular healing is one
f the major drawbacks of current polymer-based DES. Our
ata point to the role polymers play in provoking local
nflammation as well as allowing for controlled release of
rug. Both mechanisms likely play a role in the pathophys-
ology of delayed healing that underlies all cases of late stent
hrombosis at autopsy. The ISAR system demonstrates the
dvantages of a nonpolymeric system from the standpoint of
nflammation and arterial healing but also shows its draw-
acks in terms of antirestenotic efficacy, because drug release
annot be tightly controlled. Although we did not see any
ifference in percent stenosis in the nonoverlapping seg-
ents of CDES and the ISAR DES, the differential
esponse of these 2 systems has been seen in clinical trials. In
he randomized trial of a nonpolymer-based rapamycin-
luting stent versus a polymer-based paclitaxel-eluting stent
or the reduction of late lumen loss, the late loss of the ISAR
tent was 0.48 mm, far below the 0.18 mm reported for the
ypher in the SIRIUS (Sirolimus-Eluting Stent in De
ovo Native Coronary Lesions) trial (10,26).
Given this limitation, our data suggest that the ISAR
ystem may still be a valid addition to current DES
latforms, because it combines anti-restenotic efficacy with
ess interference with vascular healing.
tudy limitations. This investigation of overlapping DES in
n animal model using normal nonatherosclerotic arteries
ay have underestimated the effects of high doses of drug
nd polymer on the arterial wall, because atherosclerosis
ends to intensify inflammatory responses. Current animal
odels used in the assessment of stents are limited in their
bility to replicate human conditions, although results in the
abbit model have generally been representative of human
esponses, albeit with a different time course of healing.
onclusions
e have shown for the first time that the nonpolymeric
irolimus-coated ISAR stents implanted in the rabbit iliac
esult in less impairment in arterial healing but also less
ffective antirestenotic efficacy when compared with CDES
t 28 days. The CDES provoked significantly more fibrin,
nflammation, and endothelial damage than did the SES
nd SESED DES coated using the ISAR system. The
ifferences observed are likely due to a combination of
educed vascular inflammation and the shorter release ki-
etics and duration of tissue drug deposition of the ISAR
ompared with the CDES systems. As concerns mount
egarding late stent thrombosis, the balance may lie in favorf nonpolymeric systems that allow for less robust intimal
uppression but greater healing.
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